Vertex Pharmaceuticals Inc. said that the Food and Drug Administration has granted its request for an expedited review of its potential Hepatitis C treatment.
The FDA’s standard review time for a drug candidate is 10 months. But Cambridge-based Vertex said in a press release that the FDA has agreed to review Telaprevir in six months, with a target review date set for May 23.
As the release noted, the FDA grants priority reviews to drug candidates that offer major advances in treatment or provide a treatment where no adequate therapy exists.
Vertex added that Telaprevir has also been granted a priority review by Canadian drug regulators.